Nitraquazone is a synthetic quinone derivative that has been investigated for its potential anticancer properties. It exhibits antiproliferative activity against various cancer cell lines, including leukemia, melanoma, and breast cancer cells. Its mechanism of action involves the generation of reactive oxygen species (ROS), which can induce DNA damage and apoptosis in cancer cells. Nitraquazone also inhibits the growth of cancer cells by targeting key signaling pathways involved in cell proliferation and survival. Additionally, it has been shown to have anti-angiogenic effects, preventing the formation of new blood vessels that supply tumors with nutrients and oxygen. The compound's ability to selectively target cancer cells while sparing normal cells makes it a promising candidate for cancer treatment. Further research is ongoing to evaluate its efficacy and safety in clinical trials.'
nitraquazone: structure given in first source
ID Source | ID |
---|---|
PubMed CID | 68765 |
CHEMBL ID | 88990 |
SCHEMBL ID | 125623 |
MeSH ID | M0129378 |
Synonym |
---|
CHEMBL88990 |
nitraquazone |
56739-21-0 |
3-ethyl-1-(3-nitrophenyl)quinazoline-2,4-dione |
unii-1yf1kxp4qf |
nitraquazone [inn] |
nitraquazonum |
1yf1kxp4qf , |
nitraquazona [spanish] |
3-ethyl-1-(m-nitrophenyl)-2,4(1h,3h)-quinazolinedione |
nitraquazonum [latin] |
nitraquazona |
SCHEMBL125623 |
1-(m-nitrophenyl)-3-ethylquinazoline-2,4(1h, 3h)-dione |
GNWCRBFQZDJFTI-UHFFFAOYSA-N |
1-(m-nitrophenyl)- 3-ethylquinazoline-2,4(1h, 3h)-dione |
1-(m-nitrophenyl)-3-ethylquinazoline-2,4 (1h, 3h)-dione |
DTXSID00972177 |
3-ethyl-1-(3-nitrophenyl)quinazoline-2,4(1h,3h)-dione |
bdbm50218545 |
Q27253193 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.9000 | 0.0003 | 2.7232 | 10.0000 | AID45797 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.9000 | 0.0003 | 2.7232 | 10.0000 | AID45797 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.9000 | 0.0003 | 2.6638 | 10.0000 | AID45797 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 (µMol) | 0.0500 | 0.0000 | 1.0680 | 10.0000 | AID159645 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.9000 | 0.0003 | 2.7232 | 10.0000 | AID45797 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 (µMol) | 0.0500 | 0.0000 | 1.1040 | 10.0000 | AID159645 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 (µMol) | 0.0500 | 0.0000 | 1.4651 | 10.0000 | AID159645 |
cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 (µMol) | 0.0500 | 0.0000 | 1.1463 | 10.0000 | AID159645 |
cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0000 | 2.0724 | 10.0000 | AID159222 |
cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0003 | 1.9901 | 10.0000 | AID159222 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID195719 | Displacement of [3H]rolipram from high affinity binding site (HARBS) in rat brain membrane. | 2000 | Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23 | Synthesis and biological evaluation of 2,5-dihydropyrazol. |
AID179552 | Inhibition of [3H]rolipram binding to rat brain membranes. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | Nicotinamide ethers: novel inhibitors of calcium-independent phosphodiesterase and [3H]rolipram binding. |
AID159951 | Displacement of [3H]rolipram binding to Phosphodiesterase 4 in rat brain | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. |
AID159645 | Inhibitory potency against guinea pig ventricular phosphodiesterase 4 | 2000 | Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23 | Synthesis and biological evaluation of 2,5-dihydropyrazol. |
AID45807 | Inhibition of phosphodiesterase 4 in rat brain cortex | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. |
AID185922 | Percentage inhibition of carrageenan-induced rat foot edema at a dose of 3.2 mg/kg when administered perorally (po). | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. |
AID159222 | Inhibitory potency against guinea pig ventricular phosphodiesterase 3 | 2000 | Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23 | Synthesis and biological evaluation of 2,5-dihydropyrazol. |
AID133090 | Inhibition of immobility in mouse forced swim test by peroral dose | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. |
AID45803 | Inhibition of phosphodiesterase 4 from guinea pig lung | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. |
AID115610 | Inhibition of reserpine-induced hypothermia in mice by peroral dose | 1991 | Journal of medicinal chemistry, Feb, Volume: 34, Issue:2 | Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase. |
AID45797 | Inhibition of [3H]cAMP (NEN NET-275) binding to Calcium-Independent Phosphodiesterase from rat brain. | 1991 | Journal of medicinal chemistry, Jan, Volume: 34, Issue:1 | Nicotinamide ethers: novel inhibitors of calcium-independent phosphodiesterase and [3H]rolipram binding. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 5 (71.43) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (14.29%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |